ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's joint venture, Aleor Dermaceuticals Limited, has received US Food and Drug Administration (USFDA) Tentative Approval for Efinaconazole Topical Solution, 10%. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Shareholding for the Period Ended March 31, 2021
Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here ALEMBIC PHARMACEUTICALS LTD. - 533573 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0330 Name of the Signatory :- Charandeep Singh SalujaDesignation :- Company Secretary and Compliance Officer Alembic Pharmaceuticals Ltd - 533573 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the captioned matter, please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2021, received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. We request you to kindly take the same on record.
Alembic Pharma's injectables plant launch may face some delay
Company saw Form 483 with observations issued by US FDA for injectables plant in February Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) and / or their legal heir(s) on 1st April, 2021. We enclose herewith an intimation received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Re-Appointment Of Directors
With reference to the captioned matter, this is to inform the exchange that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors at its meeting held on 19th January, 2021 had approved the re-appointment of following Directors of the Company for a further period of 5 years w.e.f. 1st April, 2021, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting: 1. Mr. Chirayu Amin (DIN: 00242549) as Executive Director (Designated as Chairman & Chief Executive Officer) 2. Mr. Pranav Amin (DIN: 00245099) as Managing Director 3. Mr. R. K. Baheti (DIN: 00332079) as Director - Finance & CFO We hereby declare that the above referred Directors are not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. The detailed disclosure pursuant to Regulation 30(2) of Listing Regulations, 2015 is enclosed herewith as Annexure - A. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Closure of Trading Window
With reference to the captioned matter, this is to inform the exchange that in terms of the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company will remain closed from 1st April, 2021 till 48 hours after the declaration of the audited financial results for the quarter and financial year ended 31st March, 2021. The date of the Board Meeting for inter alia considering the audited financial results for the quarter and financial year ended 31st March, 2021 will be intimated in due course. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s) for the purpose of claiming those shares from the Investor Education and Protection Fund (IEPF). We enclose herewith a letter received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificate(s) published by the Company on behalf of the registered shareholder(s) and / or their legal heir(s) in English language newspaper - Business Standard on 5th March, 2021. We request you to kindly take the same on record.